Rectal cancer stage III

4 trials 2 recruiting MedDRA PT
4 Registered trials
2 Recruiting
3 Unique sponsors
3 Unique IMPs
0 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Checkpoint inhibitor (PD-1) 1 substance
RAF/BRAF inhibitor 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Phase III: 1 Phase II: 3

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase III

1 trial
  • Institut Jules Bordet Academic
    IMP not specified
    2023-506703-26-00 1 country 2024 n=264
    Recruiting

Phase II

3 trials
  • Fondazione GONO G.I. Academic
    IMP not specified
    2024-513297-21-00 1 country 2022 n=63
    Ended
  • Institut Jules Bordet Academic
    NIVOLUMAB; REGORAFENIB
    2024-516554-22-00 1 country 2021 n=90
    Ended
  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR Academic
    TISLELIZUMAB
    2025-522120-28-00 1 country 2026 n=67
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Institut Jules Bordet Academic 2 Phase II, Phase III 1
Fondazione GONO G.I. Academic 1 Phase II 0
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR Academic 1 Phase II 1
New trials by year
2021
1
2022
1
2024
1
2026
1
← All indication landscapes